AXON Neuroscience

AXON Neuroscience is a clinical-stage biotechnology company developing disease-modifying immunotherapies for Alzheimer's disease and frontotemporal lobar degeneration. Breakthrough discoveries in Alzheimer's research by AXON Neuroscience have enabled the company to create a therapeutic platform of global significance. A strategically important target product within this platform is the revolutionary therapeutic vaccine candidate for treating Alzheimer’s disease and frontotemporal lobar degeneration. AXON Neuroscience has developed unique animal models that replicate Alzheimer's disease, allowing for rapid and effective preclinical validation of the efficacy of new therapies and the preclinical evaluation of diagnostic tools. Strategic and targeted research and development have prepared AXON Neuroscience for future production of a wide range of disease-modifying drugs and diagnostic methods for Alzheimer’s disease.